Aster DM Healthcare obtains the ESB, no objection for the merger with Quality Care India

Major for health care aster DM Healthcare limited Monday October 6 said that he had received no objection letter without unfavorable observations from BSE Limited and the India Limited National Stock Exchange on October 6, 2025, in relation to its merger proposed with Quality Care India Limited.

The merger, approved earlier by the boards of directors of the two companies, will combine Quality Care India (Acceptor Company) with Aster DM Healthcare (Transferee Company) under articles 230-232 of the 2013 law on companies.

This development follows the previous deposit of Aster DM Healthcare on November 29, 2024, concerning the approval of the board of directors of the regime, and aligns with the sebi re -listing regulations, including Regulation 30 and Regulation 37, as well as the Master Circular of SEBI on the arrangement patterns by listed entities.

Read also: Aster DM Healthcare Eyes Pledge Reduction, targets strong post-fusion growth
Aster DM Healthcare had acquired the participation in Quality Care India of BCP Asia II Topco IV PTE LTD (BCP) and Centella Mauritius Holdings Limited (Centella) thanks to a sharing exchange before India quality. The merger of Qcil with Aster DM Healthcare was announced in November 2024.

The transaction was completed by acquiring 1.90.46 028 QCIE actions by Aster DM Healthcare of BCP and TPG for a value of RS 849.13 Brove, said Aster DM Healthcare in a press release. As a discharge from the total purchase consideration to pay, Aster allocated 1.86.07,969 shares (nominal value of RS 10) to BCP and Centella, he added.

The merged entity – Aster DM Quality Care – will be jointly controlled by Aster promoters and the BCP and will bring together the forces of two main health care providers with a common vision of expanding access to medical care across the country, he added.

Also read: Aster DM Healthcare oscillates for the fourth quarter; EBITDA increases 20% in annual shift

Aster DM Healthcare Ltd’s actions ended at 672.30 ₹, up 27.10, or 4.20%, on the ESB.